Summary
Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016’, provides an overview of the Venous Leg Ulcers (Crural ulcer) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
- The report reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Venous Leg Ulcers (Crural ulcer) therapeutics and enlists all their major and minor projects
- The report assesses Venous Leg Ulcers (Crural ulcer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adocia
CardioVascular BioTherapeutics, Inc.
CytoTools AG
FirstString Research, Inc.
MacroCure Ltd.
MediWound Ltd.
NovaLead Pharma Pvt. Ltd.
Pergamum AB
RegeneRx Biopharmaceuticals, Inc.
Stratatech Corporation
Tissue Therapies Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Leg Ulcers (Crural ulcer) Overview 7
Therapeutics Development 8
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview 8
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies 9
Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies 14
Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development 15
Adocia 15
CardioVascular BioTherapeutics, Inc. 16
CytoTools AG 17
FirstString Research, Inc. 18
MacroCure Ltd. 19
MediWound Ltd. 20
NovaLead Pharma Pvt. Ltd. 21
Pergamum AB 22
RegeneRx Biopharmaceuticals, Inc. 23
Stratatech Corporation 24
Tissue Therapies Limited 25
Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Biochaperone PDGF-BB - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CL-05 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
CODA-001 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CureXcell - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
CVBT-141B - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
EscharEx - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Granexin - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
LL-37 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
NLP-328 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
PAC-G - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
RGN-137 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Stathmin-1 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
VF-001 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Venous Leg Ulcers (Crural ulcer) - Dormant Projects 60
Venous Leg Ulcers (Crural ulcer) - Discontinued Products 61
Venous Leg Ulcers (Crural ulcer) - Product Development Milestones 62
Featured News & Press Releases 62
May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial 62
Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update 62
Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers 63
Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment 64
Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results 64
Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications 65
May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication 66
Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers 66
Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers 67
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 68
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds 68
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 68
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71
List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Comparative Analysis by Unknown Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H2 2016 15
Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016 16
Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H2 2016 17
Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H2 2016 18
Venous Leg Ulcers (Crural ulcer) - Pipeline by MacroCure Ltd., H2 2016 19
Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd., H2 2016 20
Venous Leg Ulcers (Crural ulcer) - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016 21
Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H2 2016 22
Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 23
Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corporation, H2 2016 24
Venous Leg Ulcers (Crural ulcer) - Pipeline by Tissue Therapies Limited, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H2 2016 60
Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H2 2016 61
List of Figures
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Targets, H2 2016 27
Number of Products by Stage and Targets, H2 2016 27
Number of Products by Mechanism of Actions, H2 2016 29
Number of Products by Stage and Mechanism of Actions, H2 2016 29
Number of Products by Routes of Administration, H2 2016 31
Number of Products by Stage and Routes of Administration, H2 2016 31
Number of Products by Molecule Types, H2 2016 33
Number of Products by Stage and Molecule Types, H2 2016 33
